Why CHRN Stock dropped -7.91% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, CHRN scores 26 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 6/20 (ROIC -9.3%; FCF yield -0.53%); Whale 13F Flow 5/20 (institutional accumulation and options positioning); Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 4/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). Every pillar scores in the lower portion of its range, and the cash-generation and forensic pillars are the weakest contributors to the total. For a prospective investor, the upside case rests on a turnaround in cash generation, which the rating does not show as currently underway: ROIC is negative and FCF yield is negative. The valuation tradeoff is that without reported earnings per share or P/E data in the source, an investor cannot benchmark the current price of $15.62 against earnings. The Roarable rating frames the risk as forensic in nature, meaning the concern centers on the quality and durability of reported financial health, not only on price momentum. Insider and institutional flow signals are also weak on the rating, which reduces the evidence for a near-term catalyst from smart-money positioning.

ChronoScale Holdings Corporation is a NASDAQ-listed issuer in the Industrials sector, within the Industrial Machinery/Components industry, per the company profile. The profile identifies the company by its sector and industry classification and reports a market capitalization of $2.3B. The source data does not describe its specific products, customers, or revenue model. Reported revenue was $71.6M for FY 2025 and $84.4M for FY 2024, per the SEC financials.

Per the market data, gross margin is 9.6%, operating margin is -18.6%, and net margin is -16.3%, with ROIC at -9.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Revenue declined from $84.4M in FY 2024 to $71.6M in FY 2025, while net loss narrowed slightly from $-11.3M to $-11.7M (a slight widening, not a narrowing). Reported cash fell from $4.5M to $1.2M over the same period.

Per the recent news feed, three items are tagged to CHRN, all carrying a YELLOW light and the "MARKET WIRE" impact label:

• A Simply Wall St report titled "ChronoScale Holdings (Nasdaq:CHRN) - Stock Analysis," covering market action, institutional positioning, and fundamental catalysts.
• A MarketBeat report on CHRN short interest and short float, updated October 2026.
• A Kalkine report asking how ChronoScale plans to reach US$1 billion of run-rate revenue.

The summaries are generic and do not disclose the specific content of their analyses, so the source data does not confirm a short-interest level or a revenue plan. The Butterfly Supply-Chain Graph lists supply chain as NONE, with no butterfly links and no proprietary signals. Risk watch items per the sources include the negative operating and net margins, negative ROIC, and declining cash balance. The price change of -8.26% and the 52-week range of $3.5 to $30 indicate high volatility, though the source does not explain the drivers.

• What is the source of the reported 52-week range move from $30 to $3.5, and does it reflect a fundamental event or a market-wide repricing?
• What are the P/E, forward P/E, EV/EBITDA, and EPS figures, which the source leaves unavailable and which are needed to benchmark the valuation?
• What is the company's debt level in dollar terms, since the source reports Debt as N/A while Debt/Equity is 0.5?
• What specific revenue plan does the Kalkine report describe for reaching US$1 billion of run-rate revenue, and what is its current revenue trajectory against that target?
• What does the MarketBeat short-interest data show for CHRN's short float, and how does it relate to the 13F and insider flow signals scored in the RQD rating?